Ran Translation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Repeat-associated non-AUG (RAN) translation is an unconventional form of protein synthesis that initiates within expanded microsatellite repeat sequences without requiring a canonical AUG start codon. Discovered in 2011 by Laura Ranum and colleagues at the University of Florida, RAN translation represents a paradigm shift in understanding how [trinucleotide repeat expansion disorders[/mechanisms/[trinucleotide-repeat-expansion[/mechanisms/[trinucleotide-repeat-expansion[/mechanisms/[trinucleotide-repeat-expansion--TEMP--/mechanisms)--FIX-- cause neuronal toxicity. Unlike classical translation, which requires scanning from a 5' cap to the first AUG codon, RAN translation can initiate in all three reading frames and from both sense and antisense repeat-containing transcripts, producing multiple toxic homopolymeric or dipeptide repeat (DPR) proteins. RAN translation has been implicated in the pathogenesis of [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--/[FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- , [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, [spinocerebellar ataxias], [myotonic dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy--TEMP--/diseases)--FIX--, and [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX--.
RAN translation was first described in Spinocerebellar Ataxia type 8 (SCA8) and myotonic dystrophy type 1 (DM1). Zu et al. (2011) demonstrated that expanded CAG repeats could be translated in all three reading frames (producing polyglutamine, polyalanine, and polyserine) without an AUG start codon, both in vitro and in vivo [1]. This finding challenged the long-held assumption that CAG repeat disorders caused toxicity solely through the canonical polyglutamine-containing protein product.
Key characteristics of RAN translation include:
No AUG requirement: RAN translation initiates at near-cognate codons (CUG, GUG, ACG) or through direct entry into the repeat sequence. The expanded repeats themselves drive initiation, possibly through formation of stable secondary structures (hairpins, G-quadruplexes) that stall scanning ribosomes (Kearse et al., 2016 [2]).
Length dependence: RAN translation efficiency increases with repeat length, typically requiring expansions beyond the pathogenic threshold (~30 repeats for most disorders). This correlates with clinical observations that longer repeats produce more severe disease (Cleary & Ranum, 2017 [3]).
Bidirectional translation: Both sense and antisense transcripts from expanded repeats undergo RAN translation, potentially doubling the repertoire of toxic products.
Multiple reading frames: Translation occurs in all three reading frames simultaneously, producing distinct peptide products from the same repeat sequence.
Stress responsiveness: RAN translation is selectively enhanced by the integrated stress response (ISR) through eIF2α phosphorylation, creating a pathological feedforward loop where cellular stress increases toxic DPR production (Green et al., 2017 [4]).
Expanded repeats form stable secondary structures that are critical for RAN translation:
These structures may recruit ribosomes through internal ribosome entry site (IRES)-like mechanisms or by stalling scanning 43S pre-initiation complexes, facilitating non-canonical initiation (Tao et al., 2015 [5]).
The hexanucleotide repeat expansion (GGGGCC)n in the [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- gene is the most common known genetic cause of both [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- and [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, accounting for approximately 40% of familial ALS and 25% of familial FTD cases. Healthy individuals carry 2–25 repeats, while affected patients typically harbor hundreds to thousands of repeats.
RAN translation of the [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- expansion produces five distinct dipeptide repeat (DPR) proteins from sense and antisense transcripts:
| DPR | Transcript | Reading Frame | Charge | Localization | Toxicity |
|---|---|---|---|---|---|
| Poly-GA (glycine-alanine) | Sense | Frame 1 | Neutral | Cytoplasmic inclusions | High |
| Poly-GP (glycine-proline) | Sense/Antisense | Frame 2 | Neutral | Cytoplasmic | Moderate |
| Poly-GR (glycine-arginine) | Sense | Frame 3 | Positive | Nuclear/nucleolar | Very high |
| Poly-PA (proline-alanine) | Antisense | Frame 1 | Neutral | Cytoplasmic | Low |
| Poly-PR (proline-arginine) | Antisense | Frame 2 | Positive | Nuclear/nucleolar | Very high |
Poly-GA is the most abundantly produced DPR and forms p62-positive cytoplasmic inclusions throughout the CNS. It contributes to toxicity through:
The arginine-containing DPRs are the most toxic and primarily localize to the nucleus and nucleolus:
Ribosomal impairment: Poly-GR binds to 60S ribosomal subunits and impairs translation elongation, causing a global translational stall and activating the ribotoxic stress response via the ZAKα-p38 signaling pathway (Moens et al., 2019 [8]).
[Nucleocytoplasmic transport] disruption: Arginine-rich DPRs interact with nuclear pore complex components and importins, disrupting nucleocytoplasmic transport. The nuclear import receptor Kapβ2/Transportin-1 modulates poly-GR neurotoxicity (Nanaura et al., 2024 [9]).
Phase separation disruption: Poly-GR and poly-PR undergo [liquid-liquid phase separation[/mechanisms/[liquid-liquid-phase-separation[/mechanisms/[liquid-liquid-phase-separation[/mechanisms/[liquid-liquid-phase-separation--TEMP--/mechanisms)--FIX-- and disrupt the dynamics of membraneless organelles, including [stress granules[/mechanisms/[stress-granules[/mechanisms/[stress-granules[/mechanisms/[stress-granules--TEMP--/mechanisms)--FIX--, nucleoli, and nuclear speckles (Lee et al., 2016 [10]).
[DNA damage]: Arginine-rich DPRs impair DNA repair by disrupting ATM signaling and sequestering DNA damage response factors.
Recent research has identified key regulators of [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- RAN translation:
MARK2 (Microtubule Affinity-Regulating Kinase 2): Acts as an eIF2α kinase that enhances RAN translation under proteotoxic stress. MARK2 inhibition reduces DPR production in patient-derived [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (Cheng et al., 2025 [11]).
Cryptic transcriptional initiation: Intronic transcriptional start sites within the [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- locus generate endogenous mRNA templates that efficiently drive RAN translation, providing a mechanism for DPR production even from intron-retained transcripts (Almeida et al., 2025 [12]).
In [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, the expanded CAG repeat in the [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- gene] undergoes RAN translation in addition to canonical translation of the polyglutamine tract:
These RAN products have been detected in HD patient brains and may contribute to toxicity beyond that of the canonical polyQ-expanded [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- (Bañez-Coronel et al., 2015 [13]).
Antisense transcription across the CAG repeat produces CUG repeat RNAs that undergo RAN translation, generating polyleucine, polycysteine, and polyalanine peptides. These antisense RAN products accumulate in HD striatum, the brain region most vulnerable to degeneration.
[SCA8] was the first disorder in which RAN translation was demonstrated. The CTG·CAG repeat expansion produces:
The TGGAA repeat expansion in SCA31 undergoes RAN translation producing poly(WNGME) pentapeptide repeat proteins. These pentapeptide products form nuclear inclusions in cerebellar Purkinje cells.
In [FXTAS[/diseases/[fxtas[/diseases/[fxtas[/diseases/[fxtas--TEMP--/diseases)--FIX--, the CGG repeat expansion in the FMR1 5' UTR undergoes RAN translation producing:
FMRpolyG is toxic to [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and disrupts the [ubiquitin-proteasome system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system--TEMP--/entities)--FIX-- and nuclear lamina integrity (Todd et al., 2013 [14]).
[Myotonic dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy--TEMP--/diseases)--FIX-- types 1 (DM1, CTG expansion in DMPK) and 2 (DM2, CCTG expansion in CNBP) both show evidence of RAN translation. In DM1, antisense CAG repeat transcripts produce polyglutamine proteins that accumulate in affected tissues. The expanded CUG RNA also sequesters MBNL1 splicing factor, compounding toxicity from both RNA gain-of-function and RAN-derived protein products.
Integrated stress response (ISR) modulation: Since eIF2α phosphorylation enhances RAN translation, ISR inhibitors such as ISRIB may reduce DPR production. However, the ISR also mediates beneficial adaptive responses, requiring careful therapeutic calibration.
[mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- pathway modulation: [mTOR[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration[/mechanisms/[mtor-neurodegeneration--TEMP--/mechanisms)--FIX-- signaling influences RAN translation efficiency; rapamycin and rapalogs may reduce DPR production.
Metformin: Has been shown to reduce RAN translation of CGG repeats in FXTAS models, possibly through AMPK-mediated signaling.
[Antisense oligonucleotides (ASOs)[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--: ASOs targeting the [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- sense transcript reduce both RNA foci and DPR production. [Tofersen[/treatments/[tofersen[/treatments/[tofersen[/treatments/[tofersen--TEMP--/treatments)--FIX---like approaches for [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- are in clinical development.
[CRISPR-based approaches[/treatments/[crispr-gene-editing[/treatments/[crispr-gene-editing[/treatments/[crispr-gene-editing--TEMP--/treatments)--FIX--: Gene editing to excise the repeat expansion or modulate transcription from the expanded locus.
Small molecules targeting repeat RNA structure: Compounds that bind the G-quadruplex or hairpin structures of expanded repeats can inhibit RAN translation initiation.
Anti-DPR antibodies: Passive immunization with antibodies against poly-GA or poly-GP has shown efficacy in [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- mouse models, reducing DPR burden and improving behavioral outcomes.
PKR pathway inhibition: Inhibiting the protein kinase R (PKR) pathway decreases RAN protein levels and improves disease phenotypes in preclinical models.
DPR proteins, particularly poly-GP, are detectable in [cerebrospinal fluid[/entities/[csf[/entities/[csf[/entities/[csf--TEMP--/entities)--FIX-- of [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- expansion carriers and serve as pharmacodynamic biomarkers in clinical trials. Reduction of CSF poly-GP levels has been used as a primary endpoint for ASO therapies targeting [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- repeat RNA.
The study of Ran Translation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 14 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 41%